MedPath

Research on Infarction With Open Arteries Using OCT and CMR

Not Applicable
Active, not recruiting
Conditions
Myocardial Infarction
Interventions
Device: OCT
Procedure: CMR
Drug: contrast agent, Gadolinium
Registration Number
NCT02270359
Lead Sponsor
NYU Langone Health
Brief Summary

The purpose of this study is to determine the prevalence of plaque disruption and to assess the composition of disrupted plaques in patients with myocardial infarction (MI) and non-obstructive coronary artery disease (CAD) using optical coherence tomography (OCT). Additionally, cardiac magnetic resonance imaging (CMR) will be used to detect myocardial abnormalities, which will be correlated to OCT findings to gain insight into the mechanisms of MI in patients with non-obstructive coronary artery disease (i.e. "open arteries").

Detailed Description

In this single center, observational study, patients of both sexes with MI who are referred for cath will be enrolled. Those who have no obstructive CAD on clinically indicated coronary angiography, defined as no stenosis of \>50% in any major epicardial vessel, will undergo coronary OCT just after the clinically indicated diagnostic angiogram, and CMR within 1 week, typically within 72-96 hours. Participants will be followed for clinical events for at least 1 year. 20 fully eligble participants will be recruited at NYU Langone Medical Center and Bellevue Hospital Center among a projected 200 enrolled patients.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
15
Inclusion Criteria
  • Acute ischemic symptoms compatible with diagnosis of acute coronary syndrome (ACS) (chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms)
  • Objective evidence of myocardial infarction (either or both of the following): Elevation of troponin to above the laboratory upper limit of normal (ULN) or ST segment elevation of ≥1mm on 2 contiguous ECG leads
  • Willing to provide informed consent and comply with all aspects of the protocol
  • Age ≥ 21 years
Read More
Exclusion Criteria
  • Stenosis ≥50% of any major epicardial vessel on invasive angiography, as determined by the angiographer at the time of clinically ordered cardiac cath.
  • History of known obstructive CAD at angiography, including history of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
  • Recent use of vasospastic agents, such as cocaine, triptans, ergot alkaloids (≤1 month)
  • Alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma
  • Coronary dissection apparent on angiography
  • Excessive coronary tortuosity which, in the opinion of the angiographer, increases the risks of OCT
  • eGFR<30 or contraindication to additional contrast needed for OCT in the opinion of the angiographer or treating physician
  • Contraindication to MRI (including but not limited to MRI-incompatible metal implants or foreign bodies)
  • Pregnancy
  • Thrombolytic therapy for STEMI (qualifying event)
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
MI without obstructive CADCMRMI without obstructive CAD, with OCT and CMR imaging
MI without obstructive CADOCTMI without obstructive CAD, with OCT and CMR imaging
MI without obstructive CADcontrast agent, GadoliniumMI without obstructive CAD, with OCT and CMR imaging
Primary Outcome Measures
NameTimeMethod
The prevalence of plaque disruption1 Week
Secondary Outcome Measures
NameTimeMethod
Prevalence and pattern of LGE and myocardial edema Prevalence of different plaque types according to OCT Proportion of patients with identifiable MI etiology based on study testing1 week

Trial Locations

Locations (1)

NYU Langone Medical Center

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath